Spironolactone |
![]() Last updated: 13/09/2025 |
![]() |
(Also known as: aldactone; spiroctan) |
|
![]() |
|
A diuretic drug used to treat fluid retention caused by chronic diseases. There is some evidence to suggest spironolactone is a prodrug. | |
---|---|---|
|
Treats fluid retention due to heart failure, kidney disease and other chronic issues. Spironolactone acts both as a diuretic and as an antihypertensive agent. | |
|
Cats; Dogs |
Approval status |
|
Approved - usually supplied as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
---|---|---|
|
Approved |
Chemical structure |
|
Spironolactone exhibits stereoisomerism, specifically multiple chiral centres that define its three-dimensional structure and pharmacological activity. The molecule contains a steroid backbone with several asymmetric carbon atoms, including positions 7, 8, 9, 10, 13, 14, and 17. These chiral centres give rise to a single, biologically active stereoisomer used in clinical formulations. Additionally, spironolactone features a spiro γ-lactone ring fused to the steroid nucleus, contributing to its unique geometry and receptor selectivity. While the marketed drug is typically a stereochemically pure compound. | |
---|---|---|
|
C₂₄H₃₂O₄S | |
|
CC(=O)SC1CC2=CC(=O)CCC2(C3C1C4CCC5(C4(CC3)C)CCC(=O)O5)C | |
|
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C | |
|
LXMSZDCAJNLERA-ZHYRCANASA-N | |
|
InChI=1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1 | |
|
Yes |
|
![]() |
Common Name | Relationship | Link |
---|---|---|
spironolactone | - | ![]() |
spironolactone ethyl acetate | Variant | ![]() |
General status |
|
Medicinal drug | |
---|---|---|
|
Sterol lactone drug | |
|
- | |
|
Synthetic production processes may generate diastereomeric impurities | |
|
Synthetic | |
|
Aldosterone antagonist. It inhibits aldosterone at the mineral corticord receptor of target cells in distal renal tubes | |
|
[Aldosterone, Antagonist] | |
|
52-01-7 | |
|
496916-40-6 | |
|
200-133-6 | |
|
- | |
|
- | |
|
5833 | |
|
Cardiovascular system: Diuretics, Aldosterone agents | |
|
QC03DA01 | |
|
No | |
|
- | |
|
416.6 | |
|
S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate | |
|
S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate | |
|
- | |
|
- | |
|
Environmental contaminant | |
|
- | |
|
Cream to light brown coloured crystalline solid |
Commercial |
|
|
|||
---|---|---|---|---|
|
Current | |||
|
1957, discovered; 1959, introduced to the market | |||
|
|
|||
|
|
|||
|
Usually formulated in tablet form for oral administration | |||
|
Spironolactone is synthesised through a multi-step chemical process that begins with a steroid precursor, typically 17alpha-hydroxyprogesterone or androstenolone, which provides the core structure. The synthesis involves key transformations such as acetylation to introduce acetyl groups, oxidation to form ketone functionalities, and cyclisation to create the characteristic gamma-lactone ring. A crucial step is thionation, where a carbonyl oxygen is replaced with sulfur using reagents like thioacetic acid, forming the thioacetyl group that enhances its anti-mineralocorticoid activity. The intermediate compounds are purified through solvent extraction, recrystallisation, and filtration. | |||
|
As microbial-based products tend to use fermentation-based production processes rather than chemical synthesis, they typically have a lower fossil fuel input in formulation and active ingredient creation, and also have reduced downstream emissions due to biodegradability and minimal soil disruption, their life-cycle GHG emissions are expected to be low. Whilst hard and precise data is not available, broad estimates suggest that typically emissions are likely to be below 5 kg CO₂e/kg. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
22.0 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
Moderate | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
134 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
6.03 X 1002 | Calculated | - | |||||||
|
2.78 | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
Moderate | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Metabolised in the liver to canrenone & other active metabolites. Eliminated in urine. | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
May cause drowsiness and mental confusion CLP data - suspected of causing cancer |
Handling issues |
|
|
|||
---|---|---|---|---|
|
Will emit toxic fumes if heated to decomposition | |||
|
Health: H351, H360F, H373 | |||
|
Not listed (Not listed) | |||
|
- | |||
|
- | |||
|
- |
|
![]() |
|
|
||
---|---|---|---|
|
spironolactone | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 13/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |